Cargando…
Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study
Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation. There are few data on the efficacy and safety in clinical practice of infliximab (CT-P13) in subcutaneous formulation (SC) for the treatment...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495964/ https://www.ncbi.nlm.nih.gov/pubmed/36140230 http://dx.doi.org/10.3390/biomedicines10092130 |
_version_ | 1784794151935541248 |
---|---|
author | Huguet, Jose M. García-Lorenzo, Victor Martí, Lidia Paredes, Jose María Ramírez, Jose Joaquin Pastor, Miguel Ruiz, Lucia Sanahuja, Ana Timoneda, Pilar Sanchís, Laura Pérez, Gloria Alemany Boscá-Watts, Marta Maia |
author_facet | Huguet, Jose M. García-Lorenzo, Victor Martí, Lidia Paredes, Jose María Ramírez, Jose Joaquin Pastor, Miguel Ruiz, Lucia Sanahuja, Ana Timoneda, Pilar Sanchís, Laura Pérez, Gloria Alemany Boscá-Watts, Marta Maia |
author_sort | Huguet, Jose M. |
collection | PubMed |
description | Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation. There are few data on the efficacy and safety in clinical practice of infliximab (CT-P13) in subcutaneous formulation (SC) for the treatment of patients with IBD. Methods: Multicenter, prospective study of patients with IBD in clinical remission, who had their treatment changed from intravenous (IV) infliximab to SC. Two groups of patients were evaluated according to whether they were on IV infliximab treatment at standard or intensified doses before the switch. Results: A total of 30 patients were on standard dosing and another 30 in intensified therapy. Treatment persistence in both groups at 6 months was greater than 95%. In both groups after the change, neither the biomarkers of inflammation nor the activity indices underwent significant changes at 3 and 6 months compared to the baseline value. Similarly, in both groups, infliximab trough levels showed a significant increase 3 and 6 months after the change to SC. No serious adverse events were registered. Conclusions: The CT-P13 SC brings a new anti-TNF era. Achieving much higher drug levels that are constant over time opens new paths to explore the management of patients with IBD: less immunogenicity, better perianal disease control and higher achievement of mucosal healing. |
format | Online Article Text |
id | pubmed-9495964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94959642022-09-23 Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study Huguet, Jose M. García-Lorenzo, Victor Martí, Lidia Paredes, Jose María Ramírez, Jose Joaquin Pastor, Miguel Ruiz, Lucia Sanahuja, Ana Timoneda, Pilar Sanchís, Laura Pérez, Gloria Alemany Boscá-Watts, Marta Maia Biomedicines Article Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation. There are few data on the efficacy and safety in clinical practice of infliximab (CT-P13) in subcutaneous formulation (SC) for the treatment of patients with IBD. Methods: Multicenter, prospective study of patients with IBD in clinical remission, who had their treatment changed from intravenous (IV) infliximab to SC. Two groups of patients were evaluated according to whether they were on IV infliximab treatment at standard or intensified doses before the switch. Results: A total of 30 patients were on standard dosing and another 30 in intensified therapy. Treatment persistence in both groups at 6 months was greater than 95%. In both groups after the change, neither the biomarkers of inflammation nor the activity indices underwent significant changes at 3 and 6 months compared to the baseline value. Similarly, in both groups, infliximab trough levels showed a significant increase 3 and 6 months after the change to SC. No serious adverse events were registered. Conclusions: The CT-P13 SC brings a new anti-TNF era. Achieving much higher drug levels that are constant over time opens new paths to explore the management of patients with IBD: less immunogenicity, better perianal disease control and higher achievement of mucosal healing. MDPI 2022-08-30 /pmc/articles/PMC9495964/ /pubmed/36140230 http://dx.doi.org/10.3390/biomedicines10092130 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huguet, Jose M. García-Lorenzo, Victor Martí, Lidia Paredes, Jose María Ramírez, Jose Joaquin Pastor, Miguel Ruiz, Lucia Sanahuja, Ana Timoneda, Pilar Sanchís, Laura Pérez, Gloria Alemany Boscá-Watts, Marta Maia Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study |
title | Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study |
title_full | Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study |
title_fullStr | Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study |
title_full_unstemmed | Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study |
title_short | Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study |
title_sort | subcutaneous infliximab [ct-p13], a true biologic 2.0. real clinical practice multicentre study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495964/ https://www.ncbi.nlm.nih.gov/pubmed/36140230 http://dx.doi.org/10.3390/biomedicines10092130 |
work_keys_str_mv | AT huguetjosem subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT garcialorenzovictor subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT martilidia subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT paredesjosemaria subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT ramirezjosejoaquin subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT pastormiguel subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT ruizlucia subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT sanahujaana subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT timonedapilar subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT sanchislaura subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT perezgloriaalemany subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy AT boscawattsmartamaia subcutaneousinfliximabctp13atruebiologic20realclinicalpracticemulticentrestudy |